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To the Editor: Unusual and 
multiresistant bacterial infections are 
increasingly reported in cystic fi bro-
sis (CF) patients (1). On January 25, 
2007, a 31-year-old man with CF (mu-
tation ΔF 508 and I 507) was admitted 
to our institution in Marseille, France, 
for lung transplantation. His immuno-
suppressive regimen included IV cy-
closporin A (for the fi rst 6 days with 
conversion to oral tacrolimus thereaf-
ter), azathioprine, and corticosteroids. 
Induction therapy that used antithy-
mocyte globulin was administered 
for the fi rst 3 days (Thymoglobuline, 
Genzyme Corporation, Naarden, the 
Netherlands). Since 2003, the patient 
was chronically colonized by methi-
cillin-resistant Staphylococcus aureus 
(MRSA), Pseudomonas aeruginosa 
(susceptible only to colistin sulfo-
methate), and Candida albicans. Pre-
emptive treatment with antimicrobial 
agents including colistin sulfomethate, 
tobramycin sulfate, ceftazidime, and 
linezolid was administered, starting 
on posttransplant day 1; prophylactic 
caspofungin, followed by inhaled am-
photericin B, was given for the fi rst 
month. Six and 9 days, respectively, 
after surgery, sputa from the patient 
showed P. aeruginosa and MRSA. 
On postoperative day 11, the pa-
tient’s clinical condition worsened. 
Leukocytes increased to 13.84 × 
109/L. In addition to P. aeruginosa 
(104 CFU/mL) and MRSA (103 CFU/
mL), culture of later sputum samples 
yielded the growth of 104 CFU/mL 
of gram-negative, catalase-positive, 
and oxidase-negative bacillus (isolate 
7120034) on CEPACIA agar (AES, 
Combourg, France) after 72 hours of 
incubation at 30°C. API 20NE, API 
20E, and VITEK 2 Auto system (bio-
Mérieux, Marcy l’Etoile, France) did 
not identify the bacillus. This bacteri-
um was multiresistant to antimicrobial 
agents, including colistin, and was sus-
ceptible only to imipenem, rifampin, 
and aminoglycosides. The fi nal iden-
tifi cation of this isolate as Acetobacter 
indonesiensis was achieved after par-
tial sequencing of 16S rRNA gene, as 
previously described (2) (GenBank 
accession no. AJ199841, 99% similar-
ity). The sequence of our isolate has 
been deposited in GenBank under the 
accession no. EF681860. The phylo-
genetic position of isolate 7120034 
among other gram-negative bacteria is 
shown in the Figure. 
Tobramycin was stopped at day 
11, colistin and ceftazidime were 
stopped at postoperative day 14, lin-
 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 14, No. 6, June 2008 997 
Figure. Phylogenetic tree showing the position of Acetobacter indonesiensis (isolate 
7120034, GenBank accession no. EF681860), in boldface, within acetic acid bacteria and 
other gram-negative rods. The tree was based on 16S rDNA comparison by the neighbor-
joining method. Numbers along the branches indicate bootstrap values.
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ezolid was maintained for 10 addition-
al days, and gentamicin (for 13 days) 
was added to the patient’s drug thera-
py on February 10. Despite this treat-
ment, A. indonesiensis was cultured 
from sputa obtained on February 16 
(104 CFU/mL) and February 20 (102 
CFU/mL), respectively. Six days later, 
leukocytes decreased to 8.62 × 109/L, 
and the patient’s condition improved. 
He was discharged at the beginning 
of March. During 7 months of follow-
up, the A. indonesiensis strain was not 
found again.
Acetic acid bacteria are gram-
negative bacilli classifi ed into the gen-
era Acetobacter, Gluconobacter, Glu-
conacetobacter, Acidomonas, and the 
recently described genus Asaia; these 
bacteria belong to the α subgroup of 
Proteobacteria (3). Isolates of this 
family are recognized as food-asso-
ciated bacteria and are able to grow 
at acidic pH (4). Three species have 
been reported as emerging pathogens 
in humans: Asaia bogorensis (in a case 
of peritonitis in a patient with a peri-
toneal dialysis catheter [5]); Granu-
libacter bethesdensis (in 3 cases of 
lymphadenitis associated with chronic 
granulomatous disease [6]); and Ac-
etobacter cibinongensis (a recent case 
of bacteremia in a patient receiving 
chronic hemodialysis for end-stage re-
nal failure [7]).
A. indonesiensis has been isolated 
from fruits and fl owers in Indonesia 
(8); only 3 reports on it have been 
published (3,8,9). In our patient, we 
believe that this multidrug-resistant 
bacterium was the primary cause of 
the infection because the patient was 
eventually cured after an adapted an-
timicrobial drug therapy. Because 
this bacterium grows easily at acidic 
pH (4), a classic condition in the CF 
airway surface liquid, acidity might 
contribute to bacterial adhesion and 
colonization (10). Because acetic acid 
bacteria have never been isolated from 
human fl ora, the source of the con-
tamination for our patient remains un-
known.
We also report the antimicrobial 
drug susceptibility of this bacterium. 
It was multiresistant, especially to 
colistin. Antimicrobial drug suscepti-
bility results were obtained by using 
Vitek 2 Auto system because of the 
absence of growth on Mueller-Hinton 
agar. This pattern was also the case for 
G. bethesdensis (6). The antimicro-
bial susceptibility of A. cibinongensis 
could not be validated because of the 
lack of interassay reproducibility (7). 
Initial antimicrobial drug therapy for 
this patient with amoxicillin, pristi-
namycin, and cefazolin did not cure 
the patient; he was eventually cured 
after the therapy was switched to to-
bramycin (7).
Our fi ndings reemphasize the 
emergence of new colistin-resistant 
pathogens in CF patients, as recently 
reported for Inquilinus limosus (1). 
The increased clinical use of nebu-
lized colistin for P. aeruginosa infec-
tion in CF patients may select specifi c 
colistin-resistant bacteria in such pop-
ulations. In summary, this report of a 
respiratory tract infection caused by 
A. indonesiensis after lung transplan-
tation in a French CF patient supports 
that this multidrug-resistant bacterium 
may be an emerging opportunistic 
pathogen in immunocompromized 
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